Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LNCaP cells treated with celastrol or vehicle for 6h

ABSTRACT: Celastrol is a natural product that affects LNCaP gene expression by 6h We used microarrays to detail the global programme of gene expression affected by celastrol treatment at 6h Keywords: drug treatment

ORGANISM(S): Homo sapiens

PROVIDER: GSE5505 | GEO | 2006/09/01

SECONDARY ACCESSION(S): PRJNA96155

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human LNCaP cells treated with celastrol or vehicle for 6h

Project description:Celastrol is a natural product that affects LNCaP gene expression by 6h; We used microarrays to detail the global programme of gene expression affected by celastrol treatment at 6h Experiment Overall Design: LNCaP cells were grown to 50% confluency and treated with celastrol for 6h prior to direct Trizol lysis and RNA isolation

2008-11-07 | E-GEOD-5505 | biostudies-arrayexpress

LNCaP cells treated with gedunin or vehicle for 6h

Project description:Gedunin is a natural product that affects LNCaP gene expression by 6h We used microarrays to detail the global programme of gene expression affected by gedunin treatment at 6h Keywords: drug treatment

2006-09-01 | GSE5506 | GEO

Androgen-starved LNCaP cells treated with celastrol and androgen, androgen alone, or vehicle alone for 24h

Project description:celastrol is a natural product that affects LNCaP androgen-signalling by 24h We used microarrays to detail the androgen-responsive program of gene expression affected by celastrol treatment at 24h Keywords: drug treatment

2006-09-01 | GSE5507 | GEO

Transcription profiling of human LNCaP cells treated with gedunin or vehicle for 6h

Project description:Gedunin is a natural product that affects LNCaP gene expression by 6h; We used microarrays to detail the global programme of gene expression affected by gedunin treatment at 6h Experiment Overall Design: LNCaP cells were grown to 50% confluency and treated with gedunin for 6h prior to direct Trizol lysis and RNA isolation

2008-11-07 | E-GEOD-5506 | biostudies-arrayexpress

Transcription profiling of human androgen starved LNCaP cells treated with celastrol and androgen, androgen alone, or vehicle alone for 24h

Project description:celastrol is a natural product that affects LNCaP androgen-signalling by 24h; We used microarrays to detail the androgen-responsive program of gene expression affected by celastrol treatment at 24h Experiment Overall Design: LNCaP cells were grown to 50% confluency and deprived of androgen, and subsequently treated with celastrol plus androgen, androgen alone, or vehicle alone for 24h prior to direct Trizol lysis and RNA isolation

2008-11-07 | E-GEOD-5507 | biostudies-arrayexpress

miRNA profiling of LNCaP cells treated with bortezomib or celastrol against untreated control group

Project description:This study is designed for exploring miRNAs affected by proteasome inhibitor treatment. LNCaP cells were treated with 100nM bortezomib or 2.5 uM celastrol for 12 hrs, and was subjected to miRNA profiling assay.

2020-12-30 | E-MTAB-6215 | biostudies-arrayexpress

Androgen-starved LNCaP cells treated with gedunin and androgen, androgen alone, or vehicle alone for 24h

Project description:Gedunin is a natural product that affects LNCaP androgen-signalling by 24h We used microarrays to detail the androgen-responsive program of gene expression affected by gedunin treatment at 24h Keywords: drug treatment

2006-09-01 | GSE5508 | GEO

Gene expression of colorectal cancer cells treated with Celastrol or compound 19-048

Project description:As a terpenoids natural product isolated from the plant Thunder God Vine, Celastrol is widely studied for its pharmacological activities, including anti-tumor activities. However, the clinical application of Celastrol is strictly limited due to its severe side effects. Without identification and validation of the target protein of Celastrol, it is difficult to determine whether its anti-tumor activities and side effects are due to inhibition of the same protein. Using a new computational tool we have developed for target discovery, peroxiredoxin I (PRDX1) was identified as the ROS-manipulating target protein of Celastrol. High-resolution crystal structure revealed the unique binding mode of Celastrol with PRDX1, via covalent reaction to the catalytic Cys-173 residue of PRDX1. New derivative compound named 19-048 with improved potency against PRDX1 and selectivity towards PRDX2~PRDX6 were synthesized. Both Celastrol and compound 19-048 effectively suppressed the proliferation of colorectal cancer cells. While these anti-tumor efficacy was significantly diminished on xenograft nude mice bearing PRDX1 knock-down colorectal cancer cells. Several downstream genes of p53 were dramatically up-regulated in the presence of Celastrol and compound 19-048. Our findings reveal that the side effects of Celastrol could be reduced via structural modification, and PRDX1 inhibition is promising for the treatment of colorectal cancer.

2022-12-31 | GSE198630 | GEO

Celastrol targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression

Project description:Purpose: This study aimed to explore the mechanism of Celastrol in improving psoriasis through single-cell transcriptomics Methods: Supplementation with intragastric administration of celastrol in C57BL/6 mice to observe its effect on IMQ-induced psoriasis. Single-cell RNA sequencing were performed to explore the role of celastrol for IMQ-induced psoriasis. Results: A natural product library was used to screen for a small molecule compound, celastrol, that could interfere with fibroblast-macrophage communication. It was demonstrated that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages, thereby blocking communication between the two cells Conclusion: We report that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages. The use of celastrol maybe a noveltherapeuticoption for psoriasis.

2024-04-20 | GSE231728 | GEO

Celastrol treatment on mouse embryonic fibroblasts (MEFs)

Project description:Celastrol has been shown to sensitize leptin receptor signaling and reduce ER stress. Current microarray data provide the gene expression profile in mouse embryonic fibroblasts (MEFs) after Celastrol treatment compared with control.

2016-07-08 | GSE84154 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data